Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

(4)(12)Generic OTFC

32,609-32,60966,834-66,834(51)0(51)Other Generic Pain

-42,73842,738-6,2596,2590583583Pain

273,366108,289381,655307,01961,492368,511(11)764OncologyProprietary OncologyTREANDA

284,900-284,900160,549-160,54977-77Other Proprietary Oncology

15,93157,29073,22113,53053,73367,2631879Generic Oncology

-15,41015,410-14,68514,685-55Oncology

300,83172,700373,531174,07968,418242,49773654OtherOther Proprietary

11,2224,10815,33013,277-13,277(15)-15Other Generic

10,680199,122209,80212,88981,58394,472(17)144122Other

21,902203,230225,13226,16681,583107,749(16)149109$  1,533,322$
462,871$  1,996,193$  1,308,412$
280,198$  1,588,61017%65%26% Europe- Primarily Europe, Middle East and Africa Proprietary products are products which are sold under patent coverage.   Generic products are products sold without patent coverage in the primary sales territory. Patent coverage may exist in other territories.   CEPHALON, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(In thousands, except share data)(Unaudited)September 30, December 31, 20102009CURRENT ASSETS:   Cash and cash equivalents

$
,208,990$
,647,635   Receivables, net

450,614376,076   Inventory, net

295,880240,576   Deferred tax assets, net

225,031243,246   Other current assets

66,78758,423Total current assets

2,247,3022,565,956   INVESTMENTS

12,59412,427   PROPERTY AND EQUIPMENT, net

500,013451,879   GOODWILL

833,358590,284   INTANGIBLE ASSETS, net

1,234,181981,857   DEBT ISSUANCE COSTS

15,36218,862   OTHER ASSETS

43,58236,830$
4,886,392$
4,658,095CURRENT LIABILITIES:   Current portion of long-term debt, net

$
44,097$
818,925   Accounts payable

100,91788,829   Accrued expenses

507,408430,209Total current liabilities

<
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International Corporation ... its wholly-owned subsidiary Renuell Int,l, Inc. has signed an ... Space Administration ("NASA") at the Johnson Space Center in ... See photos: tapplic.com/houstonphotos/ ... very pleased to announce our latest, exclusive agreement with ...
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2014  Xencor, Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... appointment of Debra Zack , M.D., Ph.D., ... Lloyd Rowland , senior vice president, chief ... "Debra,s expertise in biologics clinical development and medical ...
(Date:9/2/2014)... , Sept. 2, 2014  Synthetic Biologics, Inc. ... biologic and drug candidates targeting specific pathogens that ... results from its final preclinical toxicology study of ... guidance, this bridging study was required to move ... to prevent the devastating effects of Clostridium ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... blood cells can clog arteries. Source: National Institutes of Health. ... , a gene therapy researcher, announced on Wednesday that it ... Research grant from the National Institutes of Health. , ,The ... for the treatment of anemia, a blood disorder that kills ...
... has been tested on lab mice with no apparent ... at a recent conference. Information supporting this conclusion was ... ,Strong was optimistic of the molecules ability to inhibit ... treatments, the companys proprietary EVade Ribonucleases are effective at ...
... up 31 percent for quarter ConjuGon CEO to ... Canadian cancer drug Wisconsin DOA buys Seritis software ... Web site GE Healthcare profits up ... 31 percent from the same quarter last year, the company has ...
Cached Biology Technology:Mirus receives $1.26 million SBIR grant to combat anemia 2Cancer treatment advances as trials show no harm to mice 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:9/2/2014)... (September 2, 2014) In the battle between our ... unknown ally in bacteria-killing viruses known as phages. In ... Hospital, Partners In Health, Haiti,s National Public Health Laboratory, ... to give up their virulence in order to survive. ... found that cholera,s mutational escape from phage predation ...
(Date:9/2/2014)... September 2, 2014 A study published in ... of the American Academy of Child and Adolescent ... with a psychiatric diagnosis had an increased risk ... antipsychotics. , Using data from the nationwide Danish ... Ren Ernst Nielsen, Psychiatry, Aalborg University Hospital, Denmark, ...
(Date:9/2/2014)... their long, spiky legs and their propensity for eating ... of nightmares. And now research from North Carolina State ... into homes across the eastern United States. , "The ... pose any kind of threat to humans," says Dr. ... and lead author of a paper about the research. ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Risk of diabetes in children and adolescents exposed to antipsychotics 2Researchers find Asian camel crickets now common in US homes 2
... you ever met a cat that doesn't go crazy over ... the world don't respond to it at all, according to ... of Chemical & Engineering News, the weekly newsmagazine published by ... Catnip sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian ...
... Florida researchers say they are a step closer to ... cancers before symptoms become apparent. , The findings, currently ... Sciences, involve introducing molecularly engineered strands of DNA into ... burst after they adhere to cancer proteins. , ...
... the gene responsible for controlling a first key step in ... in the journal Nature tomorrow (Thursday 27 October 2005). , ... take place once a sperm enters an egg, giving it ... reproducing animals. , The absence or mutation of this gene ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3Scientists unpick genetics of first 15 minutes of life 2
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... Source produces a powerful, stable output from 215-400 ... source are available, providing a wavelength range of ...
... In situ detection of apoptosis and mitochondrial ... provides an early indication of the initiation ... defined as a collapse in the electrochemical ... by the change in the membrane potential ...
... an exciting product for cell-based kinetic assays ... the use of expensive HTS equipment, which ... the assay development stage. The NOVOstar offers ... as well as any other assay suitable ...
Biology Products: